PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas

Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring.

Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation

AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research.

PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients.

This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk.

Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients.

High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring.

Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients.

Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival.

Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer.

Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer.

Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types.

This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care.

Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients

Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring.

ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients

Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk.

ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients

Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression.

ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients

CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression.

ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients

Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer.

ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease.

CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients.

ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer.

CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring.

ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer.

CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies.

ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease.

Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types.

ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients.

Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment.

AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers

Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance.

AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer

HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions.

ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients

CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions.